Amylyx preps filing for its ALS drug after FDA feedbackJust a few months ago, Amylyx was talking about having to complete another clinical trial before it could Share XAmylyx preps filing for its ALS drug after FDA feedbackhttps://pharmaphorum.com/news/amylyx-preps-filing-for-its-als-drug-after-fda-feedback/
AI aims to prevent unneeded treatment for deep vein thrombosisResearchers in the UK are working on an artificial intelligence (AI) algorithm to help diagnose deep vein thrombosis Share XAI aims to prevent unneeded treatment for deep vein thrombosishttps://pharmaphorum.com/news/ai-aims-to-prevent-unneeded-treatment-for-deep-vein-thrombosis/
Theravance axes staff as lead pipeline drug flunks phase 3 trialTheravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in Share XTheravance axes staff as lead pipeline drug flunks phase 3 trialhttps://pharmaphorum.com/news/theravance-axes-staff-as-lead-pipeline-drug-flunks-phase-3-trial/
ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
EU ‘negotiating with Valneva’ over COVID-19 vaccine contractThe European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to Share XEU ‘negotiating with Valneva’ over COVID-19 vaccine contracthttps://pharmaphorum.com/news/eu-negotiating-with-valneva-over-covid-19-vaccine-contract/
Coalition formed to represent patient interests in digital healthNot enough is being done to ensure that patient voices are included in policymaking around digital health, says Share XCoalition formed to represent patient interests in digital healthhttps://pharmaphorum.com/news/coalition-formed-to-represent-patient-interests-in-digital-health/
Rome Therapeutics raises $77m for junk DNA-targeting drugsStartup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which Share XRome Therapeutics raises $77m for junk DNA-targeting drugshttps://pharmaphorum.com/news/rome-therapeutics-raises-77m-for-junk-dna-targeting-drugs/
First subject dosed in psilocybin trial for rare headache disorderThe first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial Share XFirst subject dosed in psilocybin trial for rare headache disorderhttps://pharmaphorum.com/news/first-subject-dosed-in-psilocybin-trial-for-rare-headache-disorder/
Astellas reports fourth death in halted gene therapy trialThere has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the Share XAstellas reports fourth death in halted gene therapy trialhttps://pharmaphorum.com/news/astellas-reports-fourth-death-in-halted-gene-therapy-trial/
